Assuring Access to Safe Medicines in Pregnancy and Breastfeeding
Authors:
Open Access
- 1 May 2021
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (4) , 941-945
Abstract
Scientists and regulators in Europe and the United States continue to seek methods and strategies to improve knowledge on rational use of medicines for pregnant and breastfeeding populations, an important subset of women’s health. Regulatory agencies have made strides toward improvement, but much more is needed. Recognizing the importance of international collaboration, we have begun to consider how to address these important public health issues more globally. The health of the child begins with the health of the mother.Keywords
This publication has 6 references indexed in Scilit:
- Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: A proposal for neglected tropical diseasesPLOS Neglected Tropical Diseases, 2020
- Levetiracetam Pregnancy Registry: Final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformationsBirth Defects Research, 2019
- Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule.2014
- Safety of pertussis vaccination in pregnant women in UK: observational studyBMJ, 2014
- Influenza vaccination coverage among pregnant women - 29 States and New York City, 2009-10 season.2012
- International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.2010